Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome

Share this content:
Researchers identified 15 genes that they said independently predict the survival outcome of patients with kidney renal papillary cell carcinoma.
Researchers identified 15 genes that they said independently predict the survival outcome of patients with kidney renal papillary cell carcinoma.

Analysis of gene-expression profiles of kidney renal papillary cell carcinoma (KIRP) samples revealed a group of 15 immune-related genes that correlate with survival outcome and may contribute to understanding which patients may respond to new therapeutic approaches such as immunotherapy.

The study, published in Cancer Medicine, used bioinformatics to interrogate data from 285 KIRP samples in The Cancer Genome Atlas (TCGA) to identify immune-related genes that were correlated with overall survival.1,2 The researchers input 1534 immune-related genes into their analysis to construct the signature, ultimately focusing on a group of 15 genes that they said independently predicted the survival outcome of patients with KIRP.

“In general, I thought it was a very interesting paper. There's a lot more work that needs to be done, but this is a good starting point,” said Chung-Han Lee, MD, PhD, an oncologist specializing in kidney cancers from Memorial Sloan Kettering Cancer Center in New York. For the rarer types of kidney cancer, a main challenge is this rarity — and a related challenge is the diversity of the malignancies within this subset.

The major type of kidney cancer and, hence, focus of the majority of renal cell carcinoma (RCC) research so far has been clear cell cancers, which make up approximately 70% of all cases. KIRP is much rarer, developing in 10% to 20% of patients, and is a highly heterogeneous disease, both histologically and in terms of prognosis.3,4 Despite these differences, it is often treated with many of the same drugs as other subtypes, consisting of mostly antiangiogenesis agents and mTOR inhibitors although some novel small-molecule inhibitors are currently under evaluation in clinical trials, such as agents that target the MET kinase (ClinicalTrials.gov Identifier: NCT02019693).

“We collectively group tumors as papillary, but even in this we know there are different natural histories of papillary. Aggressive and indolent types can currently be classified together. There needs to be further refining of the classification systems – at some point when we know more, these type of profilings may help us with these groupings and better selecting them for treatment,” said Dr Lee.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs